BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31068675)

  • 1. Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.
    Hellwig M; Merk DJ; Lutz B; Schüller U
    Cancer Gene Ther; 2020 May; 27(5):294-300. PubMed ID: 31068675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma.
    Merk DJ; Ohli J; Merk ND; Thatikonda V; Morrissy S; Schoof M; Schmid SN; Harrison L; Filser S; Ahlfeld J; Erkek S; Raithatha K; Andreska T; Weißhaar M; Launspach M; Neumann JE; Shakarami M; Plenker D; Marra MA; Li Y; Mungall AJ; Moore RA; Ma Y; Jones SJM; Lutz B; Ertl-Wagner B; Rossi A; Wagener R; Siebert R; Jung A; Eberhart CG; Lach B; Sendtner M; Pfister SM; Taylor MD; Chavez L; Kool M; Schüller U
    Dev Cell; 2018 Mar; 44(6):709-724.e6. PubMed ID: 29551561
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jia D; Augert A; Kim DW; Eastwood E; Wu N; Ibrahim AH; Kim KB; Dunn CT; Pillai SPS; Gazdar AF; Bolouri H; Park KS; MacPherson D
    Cancer Discov; 2018 Nov; 8(11):1422-1437. PubMed ID: 30181244
    [No Abstract]   [Full Text] [Related]  

  • 5. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma.
    Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L
    Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
    Niesen J; Ohli J; Sedlacik J; Dührsen L; Hellwig M; Spohn M; Holsten T; Schüller U
    Cancer Lett; 2020 May; 477():10-18. PubMed ID: 32112900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
    Yi J; Shi X; Xuan Z; Wu J
    Cancer Lett; 2021 Feb; 499():188-200. PubMed ID: 33253789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
    Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
    J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
    Peck B; Bland P; Mavrommati I; Muirhead G; Cottom H; Wai PT; Maguire SL; Barker HE; Morrison E; Kriplani D; Yu L; Gibson A; Falgari G; Brennan K; Farnie G; Buus R; Marlow R; Novo D; Knight E; Guppy N; Kolarevic D; Susnjar S; Milijic NM; Naidoo K; Gazinska P; Roxanis I; Pancholi S; Martin LA; Holgersen EM; Cheang MCU; Noor F; Postel-Vinay S; Quinn G; McDade S; Krasny L; Huang P; Daley F; Wallberg F; Choudhary JS; Haider S; Tutt AN; Natrajan R
    Cancer Res; 2021 Feb; 81(4):847-859. PubMed ID: 33509944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma.
    Bourdeaut F; Miquel C; Richer W; Grill J; Zerah M; Grison C; Pierron G; Amiel J; Krucker C; Radvanyi F; Brugieres L; Delattre O
    Pediatr Blood Cancer; 2014 Feb; 61(2):383-6. PubMed ID: 24115570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo.
    Lee SJ; Krauthauser C; Maduskuie V; Fawcett PT; Olson JM; Rajasekaran SA
    BMC Cancer; 2011 Apr; 11():144. PubMed ID: 21501498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation.
    Tan IL; Wojcinski A; Rallapalli H; Lao Z; Sanghrajka RM; Stephen D; Volkova E; Korshunov A; Remke M; Taylor MD; Turnbull DH; Joyner AL
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3392-3397. PubMed ID: 29531057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
    Heil C
    Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma.
    Hellwig M; Lauffer MC; Bockmayr M; Spohn M; Merk DJ; Harrison L; Ahlfeld J; Kitowski A; Neumann JE; Ohli J; Holdhof D; Niesen J; Schoof M; Kool M; Kraus C; Zweier C; Holmberg D; Schüller U
    Acta Neuropathol; 2019 Apr; 137(4):657-673. PubMed ID: 30830316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.